Emcure Pharmaceuticals Ltd
Incorporated in 1981, Emcure Pharmaceuticals
Ltd manufactures and markets pharmaceutical products globally[1]
- Market Cap ₹ 26,783 Cr.
- Current Price ₹ 1,413
- High / Low ₹ 1,580 / 889
- Stock P/E 35.6
- Book Value ₹ 235
- Dividend Yield 0.21 %
- ROCE 20.7 %
- ROE 18.5 %
- Face Value ₹ 10.0
Pros
- Company has reduced debt.
Cons
- The company has delivered a poor sales growth of 9.36% over past five years.
- Working capital days have increased from 42.1 days to 76.1 days
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals
Part of BSE 500 BSE Healthcare Nifty 500 BSE MidCap BSE Allcap
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM | |
|---|---|---|---|---|---|---|---|---|
| 4,717 | 5,049 | 5,033 | 5,855 | 5,986 | 6,658 | 7,896 | 8,181 | |
| 3,968 | 4,340 | 3,817 | 4,525 | 4,804 | 5,429 | 6,427 | 6,620 | |
| Operating Profit | 749 | 708 | 1,216 | 1,330 | 1,182 | 1,230 | 1,469 | 1,562 |
| OPM % | 16% | 14% | 24% | 23% | 20% | 18% | 19% | 19% |
| 72 | -25 | -159 | 63 | 39 | 47 | 62 | 27 | |
| Interest | 223 | 257 | 155 | 176 | 214 | 237 | 176 | 144 |
| Depreciation | 267 | 321 | 250 | 245 | 260 | 312 | 384 | 390 |
| Profit before tax | 331 | 105 | 652 | 973 | 747 | 727 | 971 | 1,055 |
| Tax % | 37% | 4% | 36% | 28% | 25% | 27% | 27% | |
| 209 | 101 | 419 | 703 | 562 | 528 | 707 | 770 | |
| EPS in Rs | 10.79 | 4.62 | 23.15 | 36.62 | 29.42 | 27.50 | 35.96 | 39.29 |
| Dividend Payout % | 32% | 0% | 4% | 8% | 7% | 7% | 8% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | 9% |
| 3 Years: | 10% |
| TTM: | 18% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | 36% |
| 3 Years: | 1% |
| TTM: | 45% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| 1 Year: | 14% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | 22% |
| 3 Years: | 20% |
| Last Year: | 19% |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|
| Equity Capital | 181 | 181 | 181 | 181 | 181 | 181 | 189 |
| Reserves | 1,654 | 1,731 | 2,092 | 1,807 | 2,320 | 2,771 | 4,257 |
| 2,128 | 2,327 | 2,310 | 2,217 | 2,334 | 2,335 | 1,023 | |
| 1,613 | 1,721 | 2,184 | 1,816 | 1,798 | 2,422 | 2,653 | |
| Total Liabilities | 5,577 | 5,960 | 6,768 | 6,021 | 6,634 | 7,709 | 8,122 |
| 2,247 | 2,382 | 2,188 | 2,044 | 2,147 | 3,125 | 3,197 | |
| CWIP | 581 | 485 | 302 | 320 | 411 | 159 | 177 |
| Investments | 0 | 0 | 0 | 25 | 25 | 318 | 95 |
| 2,749 | 3,093 | 4,278 | 3,632 | 4,050 | 4,108 | 4,652 | |
| Total Assets | 5,577 | 5,960 | 6,768 | 6,021 | 6,634 | 7,709 | 8,122 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|
| 444 | 500 | 704 | 768 | 747 | 1,097 | 852 | |
| -409 | -168 | -256 | -574 | -468 | -715 | -96 | |
| -735 | -301 | -189 | -152 | -145 | -164 | -814 | |
| Net Cash Flow | -700 | 32 | 259 | 42 | 134 | 219 | -58 |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|
| Debtor Days | 75 | 83 | 107 | 82 | 101 | 102 | 93 |
| Inventory Days | 234 | 211 | 293 | 237 | 223 | 225 | 224 |
| Days Payable | 142 | 133 | 188 | 184 | 175 | 193 | 172 |
| Cash Conversion Cycle | 167 | 161 | 212 | 135 | 148 | 134 | 145 |
| Working Capital Days | -15 | -28 | -16 | 9 | 22 | 28 | 76 |
| ROCE % | 11% | 22% | 26% | 21% | 19% | 21% |
Documents
Announcements
-
Announcement under Regulation 30 (LODR)-Newspaper Publication
8 Aug - Newspaper Publication of Unaudited Financial Results of the Company for the quarter ended June 30, 2025
-
Intimation Under Regulation 30 And 36(1)(B) Of The SEBI (LODR) Regulations, 2015, About Dispatch Of Letters To The Members Whose E-Mail Addresses Are Not Registered With The Company/ Depository Participants.
7 Aug - Dispatched letters with AGM notice, annual report links; urged KYC updates and TDS exemption docs submission.
-
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
7 Aug - Audio recording of Emcure Q1 FY26 earnings call available online.
-
Outcome Of The Board Meeting Held On August 07, 2025 To Approve The Unaudited Financial Results (Consolidated And Standalone) For The Quarter Ended June 30, 2025
7 Aug - Emcure Q1 FY26: 15.7% revenue growth, 41% PAT rise, expanded Sanofi partnership, Zuventus acquisition planned.
-
Board Meeting Outcome for Outcome Of Board Meeting Held On August 07, 2025
7 Aug - Emcure Q1 FY26: 15.7% revenue growth, 41% PAT growth, legal settlement Rs 35mn, Zuventus acquisition planned.
Concalls
-
May 2025TranscriptPPT
-
Feb 2025TranscriptPPTREC
-
Nov 2024TranscriptPPT
-
Aug 2024TranscriptPPT
Business Overview:[1][2]
EPL develops, manufactures and markets a broad range of pharmaceutical and biopharmaceutical products across a wide range of dosage forms, including oral solids, oral liquids, injectables, including liposomal and lyophilized injectables, biotherapeutics and complex APIs, including chiral molecules, iron molecules and cytotoxic products. It has a presence in all major therapeutic areas including Gynaecology, cardiology, blood-related, oncology, respiratory, CNS & HIV etc. Company has 350+ brands, with a wide network across 70+ countries.